MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cllc.2023.09.001

Медицинская библиотека · Clinical lung cancer · 2023

Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.

Desai Aakash, Smith Caleb J, Ashara Yash, Orme Jacob J, Zanwar Saurabh, Potter Ashley, Hocum Craig, Moffett J Nicole, Schwecke Anna J, Manochakian Rami, Lou Yanyan, Zhao Yujie, Ernani Vinicius, Savvides Panos, Molina Julian, Dimou Anastasios, Mansfield Aaron S, Parikh Kaushal, Leventakos Konstantinos

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Lurbinectedin has emerged as a potential treatment option for relapsed small cell lung cancer (SCLC). While clinical trials have demonstrated its efficacy and safety, real-world data are limited. This study aimed to evaluate the safety and efficacy of lurbinectedin in a real-world setting, focusing on its use as a second-line agent and beyond in SCLC patients.

METHODS

A retrospective analysis was conducted on 90 patients who received lurbinectedin between June 2020 and June 2022 within the Mayo Clinic Health System. Of these, 50 patients received lurbinectedin as a second-line agent, and 14 patients received it as a third-line or later agent. The primary outcomes assessed were overall survival (OS), progression-free survival (PFS), and treatment-related adverse events.

RESULTS

Lurbinectedin was generally well tolerated in this real-world cohort, with a median OS of 5.1 months in the second-line cohort and 5.6 months in the third-line or later cohort. Median PFS was 2.1 months in the second-line cohort and 3.4 months in the third-line or later cohort. Adverse events were manageable, with the most common being neutropenia, anemia, fatigue, and febrile neutropenia. No treatment-related deaths or grade 5 toxicities were reported.

CONCLUSION

This real-world study provides valuable insights into the safety and efficacy of lurbinectedin in relapsed SCLC. Lurbinectedin demonstrated modest efficacy and a comparable safety profile to that observed in clinical trials. However, outcomes for relapsed SCLC remain suboptimal, particularly for patients with a shorter chemotherapy-free interval and central nervous system metastases.

Для цитирования: Desai Aakash, Smith Caleb J, Ashara Yash, Orme Jacob J, Zanwar Saurabh, Potter Ashley, Hocum Craig, Moffett J Nicole, Schwecke Anna J, Manochakian Rami, Lou Yanyan, Zhao Yujie, Ernani Vinicius, Savvides Panos, Molina Julian, Dimou Anastasios, Mansfield Aaron S, Parikh Kaushal, Leventakos Konstantinos. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.. Clinical lung cancer. 2023. DOI: 10.1016/j.cllc.2023.09.001.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.